The men's health optimization market is evolving faster than any other segment of consumer healthcare. What you're paying for today may look entirely different by 2027. Here's what's coming — and what to watch — based on pipeline data, regulatory timelines, and market signals.
Oral GLP-1 Medications
The biggest near-term shift in weight management: oral semaglutide (Rybelsus) is already approved for Type 2 diabetes, and higher-dose oral formulations are in late-stage trials for obesity. Oral tirzepatide is in Phase III development. The transition from weekly injection to daily pill changes the accessibility equation entirely.
For compounding: oral GLP-1 formulations (sublingual, dissolvable, lozenges) from compounding pharmacies are already appearing on telehealth menus. The FDA's regulatory posture on compounded oral GLP-1s remains fluid — the interplay between shortage determinations, FDA compounding rules, and manufacturer supply will determine availability.
The DEA Telehealth Deadline
December 31, 2026. The current telehealth prescribing flexibilities for controlled substances (including testosterone) are set to expire. The DEA's proposed Special Registration pathway could allow continued telehealth prescribing of Schedule III substances — but the final rule hasn't been published as of mid-2026. This deadline affects every man on telehealth TRT and every platform that prescribes it.
Possible outcomes:
- Extension: The deadline gets pushed again, maintaining the status quo. This has happened before.
- Special Registration: The DEA finalizes a pathway allowing qualifying telehealth prescribers to continue without in-person visits. Adds regulatory burden to platforms but preserves access.
- Strict enforcement: Telehealth TRT prescribing requires an initial in-person visit. Platforms would need to establish local clinical partnerships or build brick-and-mortar touchpoints.
Next-Generation Testosterone Delivery
Beyond current options (injectable cypionate/enanthate, topical gel/cream, oral TU), several delivery innovations are in development:
- Long-acting injectables: Testosterone undecanoate injections (Aveed/Nebido) already provide 10–14 week dosing intervals. Longer-acting formulations could extend this further.
- Subcutaneous implants: Testopel pellets exist but require in-office insertion. Next-generation pellets with more consistent release profiles and longer durations are in development.
- Transdermal patches 2.0: Earlier testosterone patches had adhesion and skin irritation problems. Newer formulations with improved adhesive technology and delivery kinetics are entering trials.
Peptide Regulation Evolution
The FDA's ongoing Category 2 review continues to reshape the compounded peptide landscape. As of mid-2026, BPC-157 and several GH secretagogues remain restricted. The peptide community is watching for:
- Whether any Category 2 substances get reclassified to Category 1 (eligible for compounding) based on new data submissions
- The FDA's posture on sermorelin, which has the strongest compounding basis of remaining GH peptides
- Novel peptides entering clinical trials that could eventually replace restricted compounds
AI-Driven Protocol Optimization
Several men's health platforms are integrating AI analysis of bloodwork trends, symptom tracking, and treatment response data to suggest protocol adjustments. The promise: instead of standard protocols with periodic human review, AI continuously evaluates your data and flags when dose adjustments or medication changes might improve outcomes.
The reality check: AI protocol optimization is only as good as the data it's trained on. Men's health optimization has relatively small datasets compared to fields like oncology or cardiology. Early AI tools are better at pattern recognition (flagging hematocrit trends) than at novel protocol design.
The Bottom Line
Prepare for Change, Don't Chase Hype
The near-term horizon includes oral GLP-1 options that could replace injections, regulatory changes that could reshape telehealth TRT access, and continued peptide regulation. The best strategy: optimize with evidence-backed therapies available today, stay informed about what's coming, and avoid jumping to unproven modalities before the evidence matures. The men's health market rewards early evaluators and punishes early adopters.